PA
RXRX icon

Pineridge Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Pineridge Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-886
Closed -$4.48K – 557
2025
Q2 		$4.48K Hold
886
– – ﹤0.01% 319
2025
Q1 		$4.69K Hold
886
– – ﹤0.01% 315
2024
Q4 		$5.99K Buy
+886
New +$5.96K ﹤0.01% 366

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pineridge Advisors's RXRX Position: Q3 2025 in Review

Pineridge Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 886 shares — an estimated $4.48K sold.

Pineridge Advisors first reported a position in RXRX in Q4 2024 and held it in 3 quarters. The position peaked at $5.99K in Q4 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Pineridge Advisors reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Pineridge Advisors sold 886 Recursion Pharmaceuticals shares in Q3 2025, an estimated $4.48K.
  • Pineridge Advisors first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Pineridge Advisors's Recursion Pharmaceuticals position peaked at $5.99K in Q4 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Pineridge Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.